Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Gastroesophageal Reflux
Interventions
DRUG

Dexlansoprazole MR QD

Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.

Trial Locations (52)

Unknown

Hueytown

Chandler

Sierra Vista

Tucson

Sherman

Sherwood

Carmichael

Garden Grove

Laguna Hills

Long Beach

Paramount

Rancho Cucamonga

Roseville

Sacramento

San Diego

San Ramon

Tustin

Westlake Village

Bristol

Boynton Beach

Hialeah

New Smyrna Beach

Winter Haven

Augusta

Conyers

Newnan

Stockbridge

Rockford

Metairie

Prince Frederick

Stevensville

Olive Branch

Egg Harbor

Albuquerque

Rochester

Wilmington

Columbus

Oklahoma City

Yukon

Portland

Lansdale

Salisbury

Chattanooga

Johnson City

Nashville

Dallas

El Paso

Houston

South Ogden

Chesapeake

Norfolk

Lakewood

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00847808 - Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy | Biotech Hunter | Biotech Hunter